meropenem and Hemolytic-Uremic-Syndrome

meropenem has been researched along with Hemolytic-Uremic-Syndrome* in 3 studies

Other Studies

3 other study(ies) available for meropenem and Hemolytic-Uremic-Syndrome

ArticleYear
Microangiopathic haemolytic anaemia (maha) caused by non O157:H7 E-coli.
    JPMA. The Journal of the Pakistan Medical Association, 2017, Volume: 67, Issue:6

    Topics: Adult; Anemia, Hemolytic; Anti-Bacterial Agents; Diagnosis, Differential; Escherichia coli Infections; Female; Hemolytic-Uremic Syndrome; Humans; Meropenem; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Sepsis

2017
Antibiotic-Mediated Modulations of Outer Membrane Vesicles in Enterohemorrhagic Escherichia coli O104:H4 and O157:H7.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:9

    Ciprofloxacin, meropenem, fosfomycin, and polymyxin B strongly increase production of outer membrane vesicles (OMVs) in

    Topics: Anti-Bacterial Agents; Cell Membrane Structures; Ciprofloxacin; Escherichia coli Infections; Escherichia coli O104; Escherichia coli O157; Fosfomycin; Hemolytic-Uremic Syndrome; Humans; Meropenem; Microbial Sensitivity Tests; Polymyxin B; Shiga Toxin 2; Thienamycins

2017
Hemolytic-uremic syndrome and myocardial dysfunction in a 9-month-old boy.
    Paediatric anaesthesia, 2007, Volume: 17, Issue:6

    Cardiovascular dysfunction in patients with hemolytic-uremic syndrome (HUS) may be related to secondary issues such as volume overload, hypertension or electrolyte disturbances including hyperkalemia. Additionally, primary myocardial involvement has been increasingly recognized as a potential comorbid feature of HUS. We report a 9-month-old child with HUS who developed clinical signs of poor myocardial function with depressed myocardial function noted by echocardiography. Supportive care including mechanical ventilation and inotropic agents were necessary for approximately 10 days. Follow-up echocardiography revealed return of normal ventricular function. Previous reports of primary cardiac involvement with HUS have included thrombotic microangiopathy of the coronary vasculature resulting in myocardial ischemia, myocardial infarction or depressed myocardial function, myocarditis, congestive heart failure with dilated cardiomyopathy and pericardial effusion with tamponade. Given the potential for morbidity and mortality during the preoperative period in patients with HUS, anesthesiologists involved in the care of such patients should be aware of the potential for myocardial involvement in this disease process. Preoperatively, the routine evaluation of myocardial function may be indicated.

    Topics: Anemia; Anti-Bacterial Agents; Cardiomyopathies; Cardiotonic Agents; Dopamine; Electrocardiography; Hemolytic-Uremic Syndrome; Humans; Infant; Intubation, Intratracheal; Male; Meropenem; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Oliguria; Peritoneal Dialysis; Renal Dialysis; Renal Insufficiency; Respiration, Artificial; Thienamycins; Vancomycin

2007